Mephentermine
As of the edition of 20 October 2026, Mephentermine is a small molecule: marketed, first approved in 1982 (US); acts on ADRA1A, ADRA1B and ADRA1D and 6 more; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Wyamine Sulfate
- First approved
- 1 January 1982 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Baxter Healthcare
- Registered trials
- 1, 0 stopped early
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
5 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product5 company-target rows are on route B because of Mephentermine.
See the 5 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| ADRB2 | Beta-2 adrenergic receptor | P07550 |
| ADRB1 | Beta-1 adrenergic receptor | P08588 |
| ADRA2A | Alpha-2A adrenergic receptor | P08913 |
| ADRB3 | Beta-3 adrenergic receptor | P13945 |
| ADRA2B | Alpha-2B adrenergic receptor | P18089 |
| ADRA2C | Alpha-2C adrenergic receptor | P18825 |
| ADRA1D | Alpha-1D adrenergic receptor | P25100 |
| ADRA1A | Alpha-1A adrenergic receptor | P35348 |
| ADRA1B | Alpha-1B adrenergic receptor | P35368 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Baxter Healthcare | Acquired holder | 2003 to now |
| Pfizer | Earlier holder |